OKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director

Summary by AI BETAClose X

OKYO Pharma announced that Chief Development Officer and Director Gary S. Jacob purchased 3,500 ordinary shares on NASDAQ at $1.40 per share, increasing his total holding to 112,420 shares. This insider buying activity may signal confidence in the company's prospects, particularly as OKYO Pharma plans to initiate a global Phase 3 pivotal clinical trial in the second half of the year for urcosimod, enrolling approximately 111 patients for the treatment of neuropathic corneal pain.

Disclaimer*

UK 100

Latest directors dealings